Skip to search formSkip to main contentSkip to account menu

Eloxatin

Known as: Eloxatine, Sanofi Synthelabo brand of oxaliplatin, Sanofi brand of oxaliplatin 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the… 
Highly Cited
2006
Highly Cited
2006
Oxaliplatin (Eloxatin) is a third-generation platinum derivative with an in vitro and in vivo spectrum of activity distinct from… 
2004
2004
Hyperthermia is used to treat intraperitoneal colorectal carcinomatosis. In this setting, the molecular effects of oxaliplatin… 
2003
2003
Neuropathy exacerbated by exposure to cold is a dose-limiting toxicity of oxaliplatin. The incidence of this side effect is… 
Review
2002
Review
2002
Abstract. Oxaliplatin (Eloxatine) is a third-generation platinum compound which has shown a wide antitumour effect both in vitro… 
Review
2000
Review
2000
Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N'] oxalato(2-)-O,O'] platinum; Eloxatine) is a novel platinum coordination… 
Review
2000
Review
2000
Review
1998
Review
1998
  • A. Benson
  • Seminars in Oncology
  • 1998
  • Corpus ID: 43887629
Although 5-fluorouracil (5-FU) has been used to treat advanced colorectal cancer for 45 years, the drug has only a modest…